Stage IIIC Melanoma
22
0
0
11
Key Insights
Highlights
Success Rate
58% trial completion
Published Results
14 trials with published results (64%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
36.4%
8 terminated out of 22 trials
57.9%
-28.6% vs benchmark
0%
0 trials in Phase 3/4
127%
14 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (22)
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
FDG-PET in Advanced Melanoma
Dinaciclib in Treating Patients With Stage III-IV Melanoma
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma